Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1985 Jan;27(1):102–106. doi: 10.1128/aac.27.1.102

Controlled trial of enviroxime against natural rhinovirus infections in a community.

F D Miller, A S Monto, D C DeLong, A Exelby, E R Bryan, S Srivastava
PMCID: PMC176213  PMID: 2984980

Abstract

The therapeutic effect of intranasally administered enviroxime was tested against naturally occurring common colds. The double-blind evaluation was carried out in Tecumseh, Mich., during a period when rhinoviruses are usually the principal pathogen. Rhinovirus transmission followed the typical pattern during this period of study. Although there were trends indicating greater therapeutic effectiveness for enviroxime when certain nasal symptoms were considered, there were no consistent statistically significant differences between treated and untreated groups. Results were unchanged when illnesses in different periods or associated with rhinovirus isolation were examined. It was concluded that no therapeutic effect of enviroxime was demonstrated.

Full text

PDF
102

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. DeLong D. C., Reed S. E. Inhibition of rhinovirus replication in in organ culture by a potential antiviral drug. J Infect Dis. 1980 Jan;141(1):87–91. doi: 10.1093/infdis/141.1.87. [DOI] [PubMed] [Google Scholar]
  2. Hayden F. G., Gwaltney J. M., Jr Prophylactic activity of intranasal enviroxime against experimentally induced rhinovirus type 39 infection. Antimicrob Agents Chemother. 1982 Jun;21(6):892–897. doi: 10.1128/aac.21.6.892. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Landis J. R., Cooper M. M., Kennedy T., Koch G. G. A computer program for testing average partial association in three-way contingency tables (PARCAT). Comput Programs Biomed. 1979 May;9(3):223–246. doi: 10.1016/0010-468x(79)90035-7. [DOI] [PubMed] [Google Scholar]
  4. Monto A. S., Cavallaro J. J. The Tecumseh study of respiratory illness. IV. Prevalence of rhinovirus serotypes, 1966-1969. Am J Epidemiol. 1972 Nov;96(5):352–360. doi: 10.1093/oxfordjournals.aje.a121466. [DOI] [PubMed] [Google Scholar]
  5. Phillpotts R. J., Jones R. W., Delong D. C., Reed S. E., Wallace J., Tyrrell D. A. The activity of enviroxime against rhinovirus infection in man. Lancet. 1981 Jun 20;1(8234):1342–1344. doi: 10.1016/s0140-6736(81)92520-4. [DOI] [PubMed] [Google Scholar]
  6. Phillpotts R. J., Wallace J., Tyrrell D. A., Tagart V. B. Therapeutic activity of enviroxime against rhinovirus infection in volunteers. Antimicrob Agents Chemother. 1983 May;23(5):671–675. doi: 10.1128/aac.23.5.671. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES